Europe Stocks Dip, U.S. Futures Climb; Oil Steady; Markets Wrap

Europe Stocks Dip, U.S. Futures Climb; Oil Steady; Markets Wrap

(Bloomberg) -- European stocks opened lower on Wednesday while U.S. equity futures rose. Treasuries and the dollar edged lower.Declines in banks and industrial-goods firms pulled the Stoxx Europe 600 Index down. Contracts on the S&P 500 and Nasdaq 100 indexes rebounded, after turning lower in the last hour of trading Tuesday when reports questioning Moderna Inc.’s coronavirus vaccine added to concern that a successful way to beat the pandemic remains a long way off. Riskier assets had started the week on the front foot after Moderna had fueled hopes for a Covid-19 antidote.Shares in Japan and India saw the bulk of gains in a mixed Asian session, with Shanghai and Hong Kong in the red. Crude oil stalled at around $32 a barrel in New York after a four-day rally.Investors are gauging the effect of a gradual easing of coronavirus lockdowns, while awaiting progress on a 500 billion-euro ($550 billion) fiscal-stimulus...

Cisco’s Results Disappoint, Revealing a Challenging April

High-tech stalwart Cisco Systems (CSCO) was one of the first major companies to report results for the fiscal quarter that ended in April. The results posted Wednesday afternoon are more reflective of the impact of Covid-19 than those in other recent earnings calls which only reflected results through March. And the results were grim: Cisco’s revenue for its fiscal third quarter fell 8% year-over-year to about $12 billion, its worst decline in six years. And yet, its per-share adjusted earnings of 79 cents on revenue of $11.98B easily beat analysts’ bleak target of 71 cents. The service and security segments managed modest revenue growth in the quarter. And of course, usage of WebEx videoconferencing, one of Zoom’s (ZM) primary competitors, grew strongly. Cisco’s shares rose 2% following the results.Cisco entered the pandemic from a position of relative weakness. The company has been citing a “broad based slowdown” affecting results for the last...

Moderna Vaccine Trial Missing Data To Judge Vaccine Efficacy, Experts Say

Moderna, Inc.'s (NASDAQ: MRNA) claims on achieving a dose-dependent increase in immunogenicity in Phase 1 trials of its COVID-19 vaccine candidate, mRNA-1273, are not backed by sufficient data, according to vaccine experts. The Curious Case Of Antibodies Moderna made claims on Monday that all 45 subjects who received doses of its vaccine developed COVID-19 binding antibodies.In its statement, the company indicated that eight volunteers developed neutralizing antibodies. Of the two types of antibodies, neutralizing antibodies are of definitive importance. STAT's experts question whether the remaining 37 volunteers also developed neutralizing antibodies.Since the tests required for ascertaining the antibody type present in these remaining 37 volunteers will take time, the experts, interviewed by a health-oriented news portal STAT News, conclude that Moderna only has data for eight subjects. The Age Factor Phase 1 trial data indicates volunteers ranged from 18 to 55 years. The exact ages of the eight subjects that developed...

Johnson & Johnson To Discontinue Talc-Based Baby Powder in US and Canada

Johnson & Johnson (JNJ) has decided to permanently discontinue talc-based Johnson’s Baby Powder in both the US and Canada, citing declining demand and misinformation.“Demand for talc-based Johnson’s Baby Powder in North America has been declining due in large part to changes in consumer habits and fueled by misinformation around the safety of the product and a constant barrage of litigation advertising” JNJ said.However, Johnson & Johnson remains confident in the safety of talc-based Johnson’s Baby Powder. “Decades of scientific studies by medical experts around the world support the safety of our product” argued the healthcare giant, adding that it will continue to defend the product and allegations against it in the courtroom.“All verdicts against the company that have been through the appeals process have been overturned” notes JNJ.According to the statement, Johnson’s Baby Powder represents only approximately 0.5% of the total US Consumer Health business.Going forward the company will wind down...

Stock Futures Mixed on Vaccine Doubts; Yields Down: Markets Wrap

(Bloomberg) -- U.S. and European equity futures were mixed along with stocks in Asia as reports on Moderna Inc.’s coronavirus vaccine added to concern that a successful way to beat the pandemic remains a long way off. Treasuries held an overnight advance.Japan and India saw the bulk of gains in a mixed Asian session, with Shanghai and Hong Kong in the red. U.S. futures nudged up, while European contracts dropped. The S&P 500 lost ground in the final hour of trading Tuesday, and closed down. Riskier assets had started the week on the front foot after Moderna had fueled hopes for a coronavirus vaccine, but investors are struggling to maintain the optimism. Crude oil slipped below $32 a barrel in New York.“We are being fairly cautious,” Shawn Matthews, founder and chief investment officer at Hondius Capital Management LP, said on Bloomberg TV. “If you look at the economy, it feels like...

Luckin’s Stock Faces Wipeout in Rush to Sell Before Delisting

(Bloomberg) -- Luckin Coffee Inc.’s battered stock faces a renewed wave of selling on Wednesday, after Nasdaq Inc. said it planned to delist the onetime market darling that shocked investors with revelations of accounting fraud last month.The Chinese coffee chain’s shares, which have been suspended since tumbling more than 80% in early April, will resume trading at 7 a.m. in New York. Luckin announced Nasdaq’s intention to delist the company in a statement on Tuesday, saying shares will remain on the exchange pending the outcome of an appeal hearing.The prospect of delisting is likely to trigger a rush for the exits by Luckin’s remaining shareholders, adding to a long list of challenges for the company as it tries to recover from its disclosure that senior executives fabricated about $310 million in sales. Banks including Credit Suisse Group AG, Morgan Stanley and Goldman Sachs Group Inc. are among those with money at...